BJDX (Bluejay Diagnostics) 6-Month Price Index: 0.45 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJDX Bluejay Diagnostics Inc BJDX
26 GF Score
Price $0.99
! 1 Warning Sign
View Full Analysis

What is Bluejay Diagnostics 6-Month Price Index?

Bluejay Diagnostics BJDX +8.50% 26 6-Month Price Index is 0.45 as of Sep. 22, 2026. GuruFocus rates BJDX with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-22), Bluejay Diagnostics's 6-Month Price Index is 0.45.

Bluejay Diagnostics  (NAS:BJDX) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Bluejay Diagnostics 6-Month Price Index Related Terms

BJDX vs ODYY, VTAK, ESMC: 6-Month Price Index Comparison

For the Medical Devices subindustry, Bluejay Diagnostics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BJDX
26GF Score
Bluejay Diagnostics Inc BJDX
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bluejay Diagnostics  (NAS:BJDX) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.45 mean?
Bluejay Diagnostics (BJDX) has a 6-Month Price Index of 0.45 as of Sep. 22, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Bluejay Diagnostics and its competitors.
Is Bluejay Diagnostics' 6-Month Price Index too high?
Bluejay Diagnostics' current 6-Month Price Index is 0.45. Overall, Bluejay Diagnostics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' 6-Month Price Index compare to ODYY and VTAK?
Bluejay Diagnostics' 6-Month Price Index of 0.45 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Medical Devices & Instruments company?
A good 6-Month Price Index depends on the Medical Devices & Instruments industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Bluejay Diagnostics and its competitors. Bluejay Diagnostics's current 6-Month Price Index is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current 6-Month Price Index of 0.45. The current 6-Month Price Index is 0.45. Bluejay Diagnostics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current 6-Month Price Index is 0.45 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bluejay Diagnostics Business Description

Address 360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc. is a medical diagnostics company based in the United States that develops near-patient testing systems intended to improve patient outcomes. Its primary platform is the Symphony System, a rapid, cost-effective testing device designed for use in sepsis triage and monitoring of disease progression. The company's lead product candidate is an IL-6 Test for sepsis, which is designed to deliver accurate results in approximately 20 minutes from sample to result, helping medical professionals make earlier triage and treatment decisions. Bluejay targets hospitals, clinics, and other healthcare providers that require fast diagnostic information at or near the point of care. Its revenue model is expected to be based on sales of the Symphony System instruments and recurring sales of proprietary test cartridges and related consumables. The company is headquartered in the United States and focuses primarily on the domestic healthcare market.
26GF Score

Get the complete analysis for BJDX

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price